The therapeutic effect of canakinumab is mediated by blocking the IL-1 signaling in CAFs, leading to reduced infiltration of tumor suppressor cells and inhibition of tumor angiogenesis as well as tumor growth (Fig. 6). Here, IL1B is linked to neoplasm.